Patents Examined by Brian Gangle
  • Patent number: 11369671
    Abstract: An improved vaccine for immunization of waterfowl such as ducks and geese comprises an inactivated strain of a mycoplasma infecting waterfowl, such as Mycoplasma sp. strain 1220; the vaccine can include an excipient and an adjuvant. Methods for immunization of waterfowl with the vaccine are also described.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: June 28, 2022
    Assignee: GalenBio, Inc.
    Inventors: Susan Szathmary, Laszlo Stipkovits
  • Patent number: 11369644
    Abstract: Provided herein are microbial strains isolated de novo. In some instances, the bacterial strains include genera, species, and/or strains of Lactobacillus johnsonii, Lactobacillus crispatus, Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium longum, and/or Bifidobacterium longum infantis strains. These bacterial strains can be used in the treatment of dysbiosis, inflammation, and other disorders.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: June 28, 2022
    Assignees: SIOLTA THERAPEUTICS, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Nikole Kimes, Ricardo Valladares, Benjamin Fiebiger, Susan V. Lynch
  • Patent number: 11364268
    Abstract: The present subject matter provides, inter alia, compositions and methods comprising inactivated, non-viable, or dead Bacillus coagulans bacteria such as whole dead bacterial spores and/or cells and/or particles that comprise inactivated, non-viable, or dead Bacillus coagulans bacteria. Compositions and methods comprising Bacillus coagulans peptidoglycan and/or lipoteichoic acid are also provided.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: June 21, 2022
    Assignee: Ganeden Biotech, Inc.
    Inventors: David Keller, Howard Allen Cash, Sean Farmer
  • Patent number: 11357805
    Abstract: The present invention relates to compositions comprising one or more compounds and/or extracts which induce, promote and/or improve production/release/delivery/excretion of mucin from and/or in the cornea, and methods of using the compositions to treat the eye.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: June 14, 2022
    Assignee: Johnson & Johnson Surgical Vision, Inc.
    Inventors: Wen-Hwa Ting Li, Khalid Mahmood, Ramine Parsa, Manpreet Randhawa, Mingqi Bai, Kenneth T. Holeva
  • Patent number: 11357849
    Abstract: The present disclosure provides anti-nucleolin antibodies, methods of producing anti-nucleolin antibodies, and cells producing anti-nucleolin antibodies. Also provided are methods of using anti-nucleolin antibodies in treating malignant and non-malignant diseases.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: June 14, 2022
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Daniel Fernandes, Laura Schwartz, Natalie Sutkowski, Brian Hoel, Semyon Rubinchik
  • Patent number: 11359009
    Abstract: The invention provides anti-myostatin antibodies and methods of using the same. In some embodiments, an isolated anti-myostatin antibody of the present invention binds to mature myostatin, and uptake of the antibody into cells is enhanced when complexed with the antigen. The invention also provides isolated nucleic acids encoding an anti-myostatin antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. Anti-myostatin antibodies of the present invention may be for use as a medicament. Anti-myostatin antibodies of the present invention may be for use in treating a muscle wasting disease. Anti-myostatin antibodies of the present invention may be for use in increasing mass of muscle tissue.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 14, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshinao Ruike, Taichi Kuramochi
  • Patent number: 11360081
    Abstract: A new cell line and an antibody for determining the activity of botulinum toxin are disclosed. Also disclosed is a method of determining the activity of botulinum toxin using the cell line and/or the antibody.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: June 14, 2022
    Assignee: HUGEL INC.
    Inventors: Chee Gun Lee, Ji Hyun Oum, Vijayakumar Ajay, Xiangai Gui
  • Patent number: 11359025
    Abstract: Provided herein are antibodies specific for Interleukin-1 receptor accessory protein (IL1-RAP).
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: June 14, 2022
    Assignee: Cantargia AB
    Inventors: Ying Ping Jiang, Jagath R. Junutula, Leonard G. Presta
  • Patent number: 11360091
    Abstract: A method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset. The invention also relates to a method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of diagnosing and prognosing ACS.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: June 14, 2022
    Assignees: ALFRED HEALTH, BAKER IDI HEART AND DIABETES INSTITUT HOLDINGS LTD.
    Inventor: Anthony Dart
  • Patent number: 11351208
    Abstract: The present disclosure relates to a method of altering intestinal microbiome in a patient having cystic fibrosis comprising administering at least one of Bifidobacterium and/or Bacteroides to a patient and allowing the Bifidobacterium and/or Bacteroides to alter the intestinal microbiome.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: June 7, 2022
    Assignees: Trastees of Dartmouth College, Dartmouth-Hitchcock Clime
    Inventors: George A. O'Toole, Juliette C. Madan
  • Patent number: 11344584
    Abstract: The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacterium Gemella sanguinis and their uses in treating metabolic-related diseases or disorder.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: May 31, 2022
    Assignee: Second Genome, Inc.
    Inventors: Andrew Wonhee Han, Bernat Baeza Raja, Shoko Kawana, Mitsuko Lynn Yamamoto, Karim Dabbagh, Todd Zachary DeSantis
  • Patent number: 11331349
    Abstract: The invention provides a method for the treatment or prevention of GI tract dysbiosis in a subject, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 17, 2022
    Assignees: NORGES MILJO-OG BIOVITENSKAPELIGE UNIVERSITET (NMBU), SYKEHUSET OSTFOLD HF, UNIVERSITY OF COPENHAGEN
    Inventors: Tor Lea, Charlotte Kleiveland, Karsten Kristiansen, Benjamin Anderschou Holbech Jensen, Jacob Bak Holm, Ida Sogaard Larsen, Morten Jacobsen
  • Patent number: 11331350
    Abstract: The present invention relates to an anti-cancer regulatory response and immunotherapy by Mycobacterium paragordonae (M. paragordonae). Mycobacterium paragordonae according to an aspect has cancer cytotoxicity mediated by natural killer cells or T cells as well as cytotoxicity against cancer cells, and inhibits activation of cancer cytotoxicity regulatory T cells of macrophages or dendritic cells to induce an immune response, thereby inhibiting tumor formation and thus being useful for a cancer immunotherapeutic agent.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: May 17, 2022
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Bum-Joon Kim, So-Young Lee
  • Patent number: 11318192
    Abstract: Provided herein are proteins that include at least one B cell domain and at least one T cell domain. Also provided are compositions that include one or more of the proteins and methods for using the proteins.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: May 3, 2022
    Assignee: Epitopix, LLC
    Inventors: Lisa Herron-Olson, Patricia Tam, Drew M. Catron, Daryll A. Emery
  • Patent number: 11318172
    Abstract: Provided is use of a genetically engineered bacterium of attenuated Salmonella typhimurium for treating liver cancer. The bacterium is attenuated Salmonella typhimurium VNP20009 carrying a plasmid cloned with a methioninase gene. Also provided is a construction method of the bacterium.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: May 3, 2022
    Assignee: GUANGZHOU SINOGEN PHARMACEUTICAL CO., LTD
    Inventors: Allan Zijian Zhao, Sujin Zhou, Yan Lin, Zhenggang Zhao, Fanghong Li
  • Patent number: 11305002
    Abstract: Immunogenic peptides, fusion polypeptides, and carrier molecules which include the immunogenic peptides, and immunogenic compositions which include these immunogenic peptides, fusion polypeptides, and/or carrier molecules bearing the peptides, and which are able to elicit antibody production against Haemophilus influenzae (Hi), are disclosed. Also disclosed are methods of their use in causing an antibody response against one or more strains of Hi.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: April 19, 2022
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Terrence L. Stull, Daniel J. Morton, Thomas W. Seale, Paul W. Whitby
  • Patent number: 11306143
    Abstract: Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist (e.g., an antibody) in combination with a TIM-4 antagonist (e.g., an antibody).
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: April 19, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Sean E. Doyle, Mark J. Selby, Eric Chadwick
  • Patent number: 11298570
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: April 12, 2022
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Angela M. Christiano, Raphael Clynes
  • Patent number: 11292824
    Abstract: Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises ?2,3- and ?2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using ?2,3-sialyltransferase.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: April 5, 2022
    Assignee: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard White
  • Patent number: 11280791
    Abstract: In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases. In another aspect, the present disclosure provides glutamine-containing substrates (or Q-tag substrates) that are more resistant to proteases/clipping and therefore, more stable, than other Q-tag substrates, and their uses in substrate tags for cross-linking to an amine-donor tag via an isopeptide bond mediated by a microbial transglutaminase.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: March 22, 2022
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Thomas Albert, Frank Bergmann, Victor Lyamichev, Mohamed Yosry Hassan Mohamed, Tobias Oelschlaegel, Jigar Patel, Michael Schraeml, Wojtek Steffen, Thomas Streidl